|
1
|
Ostrom MP, Gopal A, Ahmadi N, Nasir K,
Yang E, Kakadiaris I, Flores F, Mao SS and Budoff MJ: Mortality
incidence and the severity of coronary atherosclerosis assessed by
computed tomography angiography. J Am Coll Cardiol. 52:1335–1343.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mizuno Y, Jacob RF and Mason R:
Inflammation and the development of atherosclerosis. J Atheroscler
Thromb. 18:351–358. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motojima K: Peroxisome
proliferator-activated receptor (PPAR): structure, mechanisms of
activation and diverse functions. Cell Struct Funct. 18:267–277.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hiukka A, Maranghi M, Matikainen N and
Taskinen MR: PPARα: an emerging therapeutic target in diabetic
microvascular damage. Nat Rev Endocrinol. 6:454–463. 2010.
|
|
5
|
Wilson JL, Duan R, El-Marakby A, Alhashim
A and Lee DL: Peroxisome proliferator activated receptor-α agonist
slows the progression of hypertension, attenuates plasma
interleukin-6 levels and renal inflammatory markers in angiotensin
II infused mice. PPAR Res. 2012:6459692012.
|
|
6
|
Fruchart JC, Duriez P and Staels B:
Peroxisome proliferator-activated receptor-alpha activators
regulate genes governing lipoprotein metabolism, vascular
inflammation and atherosclerosis. Curr Opin Lipidol. 10:245–257.
1999. View Article : Google Scholar
|
|
7
|
Ding JL, Zhou ZG, Zhou XY, Zhou B, Wang L,
Wang R, Zhan L, Sun XF and Li Y: Attenuation of acute pancreatitis
by peroxisome proliferator-activated receptor-α in rats: the effect
on Toll-like receptor signaling pathways. Pancreas. 42:114–122.
2013.
|
|
8
|
Desvergne B and Wahli W: Peroxisome
proliferator-activated receptors: nuclear control of metabolism.
Endocr Rev. 20:649–688. 1999.PubMed/NCBI
|
|
9
|
Devchand PR, Keller H, Peters JM, Vazquez
M, Gonzalez FJ and Wahli W: The PPARalpha-leukotriene B4 pathway to
inflammation control. Nature. 384:39–43. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heun R, Kölsch H, Ibrahim-Verbaas CA,
Combarros O, Aulchenko YS, Breteler M, Schuur M, van Duijn CM,
Hammond N, Belbin O, Cortina-Borja M, Wilcock GK, Brown K, Barber
R, Kehoe PG, Coto E, Alvarez V, Lehmann MG, Deloukas P, Mateo I,
Morgan K, Warden DR, Smith AD and Lehmann DJ: Interactions between
PPAR-α and inflammation-related cytokine genes on the development
of Alzheimer’s disease, observed by the epistasis project. Int J
Mol Epidemiol Genet. 3:39–47. 2012.
|
|
11
|
Lee JW, Bajwa PJ, Carson MJ, Jeske DR,
Cong Y, Elson CO, Lytle C and Straus DS: Fenofibrate represses
interleukin-17 and interferon-γ expression and improves colitis in
interleukin-10-deficient mice. Gastroenterology. 133:108–123.
2007.PubMed/NCBI
|
|
12
|
Liu Y, Jiang H, Liu W, Shang H, Tang Y,
Zhu R and Li B: Effects of fluvastatin therapy on serum
interleukin-18 and interleukin-10 levels in patients with acute
coronary syndrome. Acta Cardiol. 65:285–289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miller AM, McPhaden AR, Preston A,
Wadsworth RM and Wainwright CL: TNFα increases the inflammatory
response to vascular balloon injury without accelerating neointimal
formation. Atherosclerosis. 179:51–59. 2005.
|
|
14
|
Mobarrez F, He S, Bröijersen A, Wiklund B,
Antovic A, Antovic J, Egberg N, Jörneskog G and Wallén H:
Atorvastatin reduces thrombin generation and expression of tissue
factor, P-selectin and GPIIIa on platelet-derived microparticles in
patients with peripheral arterial occlusive disease. Thromb
Haemost. 106:344–352. 2011. View Article : Google Scholar
|
|
15
|
Jeanpierre E, Le Tourneau T, Zawadzki C,
Van Belle E, Mouquet F, Susen S, Ezekowitz MD, Staels B, Jude B and
Corseaux D: Beneficial effects of fenofibrate on plaque
thrombogenicity and plaque stability in atherosclerotic rabbits.
Cardiovasc Pathol. 18:140–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yeh CH, Chen TP, Lee CH, Wu YC, Lin YM and
Lin PJ: Cardiomyocytic apoptosis following global cardiac ischemia
and reperfusion can be attenuated by peroxisome
proliferator-activated receptor alpha but not gamma activators.
Shock. 26:262–270. 2006. View Article : Google Scholar
|
|
17
|
Buchanan MR and Brister SJ: Inhibition of
chronic vessel wall intimal hyperplasia following acute
anticoagulant treatment: Relative effects of heparin and dermatan
sulphate. Thromb Res. 91:157–167. 1998. View Article : Google Scholar
|
|
18
|
Jia XL, Li SY, Dang SS, Cheng YA, Zhang X,
Wang WJ, Hughes CE and Caterson B: Increased expression of
chondroitin sulphate proteoglycans in rat hepatocellular carcinoma
tissues. World J Gastroenterol. 18:3962–3976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Libby P, Ridker PM and Hansson GK:
Progress and challenges in translating the biology of
atherosclerosis. Nature. 473:317–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chamouton J and Latruffe N: PPARα/HNF4α
interplay on diversified responsive elements. Relevance in the
regulation of liver peroxisomal fatty acid catabolism. Curr Drug
Metab. 13:1436–1453. 2012.
|
|
21
|
Soulitzis N, Karyotis I, Delakas D and
Spandidos DA: Expression analysis of peptide growth factors VEGF,
FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic
hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
|
|
22
|
Baritaki S, Sifakis S, Huerta-Yepez S,
Neonakis IK, Soufla G, Bonavida B and Spandidos DA: Overexpression
of VEGF and TGF-β1 mRNA in Pap smears correlates with progression
of cervical intraepithelial neoplasia to cancer: implication of YY1
in cervical tumorigenesis and HPV infection. Int J Oncol. 31:69–79.
2007.
|
|
23
|
Arvanitis DA and Spandidos DA:
Deregulation of the G1/S phase transition in cancer and squamous
intraepithelial lesions of the uterine cervix: A case control
study. Oncol Rep. 20:751–760. 2008.PubMed/NCBI
|
|
24
|
Gervois P, Chopin-Delannoy S, Fadel A,
Dubois G, Kosykh V, Fruchart JC, Najïb J, Laudet V and Staels B:
Fibrates increase human REV-ERBα expression in liver via a novel
peroxisome proliferator-activated receptor response element. Mol
Endocrinol. 13:400–409. 1999.
|
|
25
|
Stoll G and Bendszus M: Inflammation and
atherosclerosis novel insights into plaque formation and
destabilization. Stroke. 37:1923–1932. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Li D, Chen J, Xie J, Bandyopadhyay
S, Zhang D, Nemarkommula AR, Liu H, Mehta JL and Hermonat PL:
Inhibition of atherogenesis in LDLR knockout mice by systemic
delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis.
188:19–27. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kleemann R, Zadelaar S and Kooistra T:
Cytokines and atherosclerosis: a comprehensive review of studies in
mice. Cardiovasc Res. 79:360–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Di Paola R, Impellizzeri D, Torre A,
Mazzon E, Cappellani A, Faggio C, Esposito E, Trischitta F and
Cuzzocrea S: Effects of palmitoylethanolamide on intestinal injury
and inflammation caused by ischemia-reperfusion in mice. J Leukoc
Biol. 91:911–920. 2012.PubMed/NCBI
|
|
29
|
Standage SW, Caldwell CC, Zingarelli B and
Wong HR: Reduced peroxisome proliferator-activated receptor α
expression is associated with decreased survival and increased
tissue bacterial load in sepsis. Shock. 37:164–169. 2012.
|
|
30
|
Salagianni M, Galani IE, Lundberg AM,
Davos CH, Varela A, Gavriil A, Lyytikäinen LP, Lehtimäki T, Sigala
F, Folkersen L, Gorgoulis V, Lenglet S, Montecucco F, Mach F, Hedin
U, Hansson GK, Monaco C and Andreakos E: Toll-like receptor 7
protects from atherosclerosis by constraining ‘inflammatory’
macrophage activation. Circulation. 126:952–962. 2012.PubMed/NCBI
|
|
31
|
Zhou B, Pan Y, Hu Z, Wang X, Han J, Zhou
Q, Zhai Z and Wang Y: All-trans-retinoic acid ameliorated high fat
diet-induced atherosclerosis in rabbits by inhibiting platelet
activation and inflammation. J Biomed Biotechnol. 2012:2596932012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trompet S, Pons D, De Craen AJ, Slagboom
P, Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley
BM, Ford I, Hyland M, Gaw A, Macfarlane PW, Packard CJ, Norrie J,
Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG and Jukema
JW: Genetic variation in the interleukin-10 gene promoter and risk
of coronary and cerebrovascular events: the PROSPER study. Ann NY
Acad Sci. 1100:189–198. 2007. View Article : Google Scholar
|
|
33
|
van Exel E, Gussekloo J, de Craen A,
Bootsma-van der Wiel A, Frölich M and Westendorp R: Inflammation
and stroke: the Leiden 85-Plus Study. Stroke. 33:1135–1138.
2002.PubMed/NCBI
|
|
34
|
Lakoski SG, Liu Y, Brosnihan KB and
Herrington DM: Interleukin-10 concentration and coronary heart
disease (CHD) event risk in the estrogen replacement and
atherosclerosis (ERA) study. Atherosclerosis. 197:443–447. 2008.
View Article : Google Scholar : PubMed/NCBI
|
